

Bacterial vaginosis - Pipeline Insight, 2021

<https://marketpublishers.com/r/BC0489C4BAFEN.html>

Date: May 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: BC0489C4BAFEN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Bacterial vaginosis - Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Bacterial vaginosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Bacterial vaginosis Understanding

Bacterial vaginosis: Overview

Bacterial vaginosis is the most common cause of abnormal vaginal discharge or malodor, affecting up to one third of US women. Most women with bacterial vaginosis are unaware of the infection, making it difficult to diagnose in the absence of a microscopic examination of vaginal discharge or using point-of-care testing. Untreated bacterial vaginosis elevates the risk of postoperative surgical infections in women undergoing obstetric and gynecological procedures. Treatment with antimicrobial agents that target bacterial vaginosis has been shown to reduce the rate of postoperative infections following hysterectomy and surgical abortions.

'Bacterial vaginosis - Pipeline Insight, 2021' report by DelveInsight outlays

comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bacterial vaginosis pipeline landscape is provided which includes the disease overview and Bacterial vaginosis treatment guidelines. The assessment part of the report embraces, in depth Bacterial vaginosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bacterial vaginosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Bacterial vaginosis R&D. The therapies under development are focused on novel approaches to treat/improve Bacterial vaginosis.

Bacterial vaginosis Emerging Drugs Chapters

This segment of the Bacterial vaginosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bacterial vaginosis Emerging Drugs

DARE-BV1: Dare Bioscience

DARE-BV1 is a thermosetting vaginal gel formulated with clindamycin phosphate 2% designed for prolonged, localized release of the antibiotic. The drug is currently in phase 3 of clinical development for the treatment of patients with Bacterial vaginosis.

LACTIN-V: Osel Inc

Osel's LACTIN-V is a live biotherapeutic product addressing women's health disorders. LACTIN-V is under IND for preventing BV and rUTI. It contains *Lactobacillus*

crispatus CTV-05, a single strain of hydrogen peroxide-producing vaginal *Lactobacillus* that is part of the natural vaginal microbiome of many healthy women. LACTIN-V targets clinical indications associated with dysbiosis of the vaginal microbiota where hydrogen peroxide-producing lactobacilli are depleted, such as bacterial vaginosis (BV) and recurrent urinary tract infections (rUTI). LACTIN-V is delivered vaginally with a proprietary applicator. . The drug is currently in phase 2 of clinical development for the treatment of patients with Bacterial vaginosis.

Further product details are provided in the report

Bacterial vaginosis: Therapeutic Assessment

This segment of the report provides insights about the different Bacterial vaginosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Bacterial vaginosis

There are approx. 4+ key companies which are developing the therapies for Bacterial vaginosis. The companies which have their Bacterial vaginosis drug candidates in the most advanced stage, i.e. phase III include, Dare Bioscience.

Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Bacterial vaginosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bacterial vaginosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bacterial vaginosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bacterial vaginosis drugs.

Bacterial vaginosis Report Insights

- Bacterial vaginosis Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Bacterial vaginosis Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Bacterial vaginosis drugs?

How many Bacterial vaginosis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bacterial vaginosis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bacterial vaginosis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Bacterial vaginosis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Lubris Biopharma

Osel Inc

Evoform Biosciences

LUCA Biologics

Melinta Therapeutics

TenNor Therapeutics

Gedea Biotech

Pharmiva

Key Products

DARE-BV1

LACTIN-V

Radezolid

TNP 2198

Contents

Introduction

Executive Summary

Bacterial vaginosis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Bacterial vaginosis – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Bacterial vaginosis companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Bacterial vaginosis Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

DARE-BV1: Dare Bioscience

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

LACTIN-V: Osel Inc

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Bacterial vaginosis Key Companies

Bacterial vaginosis Key Products

Bacterial vaginosis- Unmet Needs

Bacterial vaginosis- Market Drivers and Barriers

Bacterial vaginosis- Future Perspectives and Conclusion

Bacterial vaginosis Analyst Views

Bacterial vaginosis Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Bacterial vaginosis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Bacterial vaginosis

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Bacterial vaginosis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/BC0489C4BAFEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BC0489C4BAFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970